P/E ratio for Eterna Therapeutics (ERNA)
P/E ratio as of May 2024 (TTM): -0.3156
According to Eterna Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.315603. At the end of 2021 the company had a P/E ratio of -1.50.
P/E ratio history for Eterna Therapeutics from 2021 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | -1.50 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | 15.7 | -5,084.59% | 🇫🇷 France |
 Baxter BAX | 7.88 | -2,596.46% | 🇺🇸 USA |
 Omeros Corporation OMER | 5.31 | -1,783.29% | 🇺🇸 USA |
 Geron GERN | -12.0 | 3,702.25% | 🇺🇸 USA |
 Genetic Technologies GENE | N/A | N/A | 🇦🇺 Australia |
 Teva Pharmaceutical Industries TEVA | -6.99 | 2,114.81% | 🇮🇱 Israel |
 Bio-Techne TECH | 46.8 | -14,925.52% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.